Safety of neuraminidase inhibitors for influenza

Research output: Contribution to journalReview articleResearchpeer-review

11 Citations (Scopus)

Abstract

Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.

Original languageEnglish
Pages (from-to)603-608
Number of pages6
JournalExpert Opinion on Drug Safety
Volume5
Issue number5
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Neuraminidase
Human Influenza
Zanamivir
Oseltamivir
Safety
Randomized Controlled Trials
Therapeutics

Cite this

@article{90a286250b514bd683b7e9ba4e02d743,
title = "Safety of neuraminidase inhibitors for influenza",
abstract = "Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.",
author = "Mark Jones and {Del Mar}, Chis",
year = "2006",
month = "9",
doi = "10.1517/14740338.5.5.603",
language = "English",
volume = "5",
pages = "603--608",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare USA",
number = "5",

}

Safety of neuraminidase inhibitors for influenza. / Jones, Mark; Del Mar, Chis.

In: Expert Opinion on Drug Safety, Vol. 5, No. 5, 09.2006, p. 603-608.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Safety of neuraminidase inhibitors for influenza

AU - Jones, Mark

AU - Del Mar, Chis

PY - 2006/9

Y1 - 2006/9

N2 - Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.

AB - Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.

UR - http://www.scopus.com/inward/record.url?scp=33747499143&partnerID=8YFLogxK

U2 - 10.1517/14740338.5.5.603

DO - 10.1517/14740338.5.5.603

M3 - Review article

VL - 5

SP - 603

EP - 608

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 5

ER -